stockportfolio.pro
Viking Therapeutics, Inc. (VKTX)
Healthcare · Biotechnology · NasdaqCM
Viking Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-14.73M | $-20.58M | $-22.06M | $-25.78M | $-39.49M | $-54.99M | $-68.87M | $-85.89M | $-109.96M | $-359.64M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Viking Therapeutics, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of Viking Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VKTX in your portfolio →
Viking Therapeutics, Inc. financial history by metric
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc. — frequently asked questions
What is Viking Therapeutics, Inc.'s revenue?
Viking Therapeutics, Inc. (VKTX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Viking Therapeutics, Inc. profitable?
No — VKTX reported a net loss of $-359.64M in fiscal 2025.
What is VKTX's P/E ratio?
Viking Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Viking Therapeutics, Inc. have?
As of fiscal year 2025, VKTX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Viking Therapeutics, Inc.'s market cap?
Viking Therapeutics, Inc. (VKTX) has a market capitalization of about $3.22B, based on the latest data in our nightly-refreshed cache.
When does Viking Therapeutics, Inc.'s fiscal year end?
VKTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Viking Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.